Secondary diagnostic testing for myasthenia gravis when first-line diagnostic tests are negative. Screen for presence of thymoma in patients with myasthenia gravis.
New York DOH Approval Status
Plain Red or Serum Separator Tube (SST).
Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min. 0.5 mL)
Refrigerated. Also acceptable: Frozen
Moderately icteric specimens.
After separation from cells: Ambient: 72 hours; Refrigerated: 1 week; Frozen: 1 month (avoid multiple freeze/thaw cycles)
Semi-Quantitative Enzyme-Linked Immunosorbent Assay
|0.45 IV or less
The presence of titin antibody is associated with late onset of myasthenia gravis (MG) and a variable risk for thymoma. Titin antibody may be detected in 20-40 percent of all patients with MG; higher frequency in older population as a whole.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
|0.00-0.45 IV: Negative
0.46-0.71 IV: Indeterminate
0.72 IV or greater: Positive
Laboratory Developed Test (LDT)
|Component Test Code*
|Component Chart Name
- Tintin Ab